ZEAL Zealand Pharma A/S

-0.01  -0%
Previous Close 18.28
Open 18.55
Price To Book 3.42
Market Cap 577619077
Shares 31,615,713
Volume 2,538
Short Ratio
Av. Daily Volume 7,935

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced March 6, 2019.
Congenital hyperinsulinism
Phase 3 data released September 18, 2018. Endpoints met.
Severe hypoglycemia in diabetes
Phase 3 trial met primary endpoint - March 2018.
Severe hypoglycemia in diabetes
Phase 3 data due 2020.
Short bowel syndrome
Phase 3 data mid-2019.
Severe hypoglycemia in diabetes - children
Phase 2b trial to be completed 1H 2019.
Dasiglucagon dual-hormone pump therapy

Latest News

  1. Zealand Pharma announces amendments to its Articles of Association following the granting of warrants
  2. Zealand Pharma to attend ABG Sundal Collier Small & Mid Cap Seminar
  3. Zealand Pharma grants new warrants under employee warrant program
  4. Zealand Pharma to attend Kempen Life Sciences Conference
  5. Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
  6. Zealand Pharma announces Emmanuel Dulac as new CEO
  7. Zealand Pharma’s Annual General Meeting in 2019
  8. Zealand Pharma to attend Needham Healthcare Conference
  9. Total number of shares and voting rights in Zealand Pharma at March 31, 2019
  10. Zealand Pharma announces completion of the share subscription by Alexion Pharmaceuticals, Inc. and registration of capital increase
  11. Zealand Pharma increases its share capital as a consequence of a new issue of shares
  12. Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
  13. Zealand Pharma convenes its Annual General Meeting 2019
  14. 3 Top Biotech Stocks to Buy in March
  15. Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
  16. Zealand Pharma announces registration of executive management and an update of the Articles of Association
  17. Changes to Zealand Pharma’s Executive Management
  18. Zealand Pharma to attend JP Morgan Healthcare Conference and Oddo BHF Forum